Capital One profit beats estimates, shares climb

Capital One Financial Corp. said Thursday it had net income of $1.1 billion, or $1.98 a share, in the third quarter, compared with $1.1 billion, or $1.86 a share, in the year-earlier period. Adjusted EPS came to $1.99, beating the FactSet consensus of $1.95. Revenue rose 4% to $5.9 billion, matching the FactSet consensus. The company said its net interest margin rose 17 basis points to 6.73%, while provisions for loan losses fell 3% to $1.1 billion. Shares rose 3.8% in after-hours trade, but are down 9.3% in the year so far, while the S&P 500 has lost 0.4%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Skechers stock craters 28% as company posts weaker-than-expected quarterly sales

Skechers USA Inc. shares tumbled 28% in after-hours trade Thursday, after the footwear company’s third-quarter sales fell short of analyst estimates. Skechers said it had net income of $66.6 million, or 43 cents a share, in the quarter, compared with $51.1 million, or 33 cents a share, in the year-earlier period. Sales rose to $856.2 million from $674.3 million. The FactSet consensus was for EPS of 54 cents and sales of $877 million. The company said the strong dollar, deferred rent costs related to its new Fifth Avenue store, which opened in the quarter, legal costs relating to personal injury suits and other legal fees shaved about 15 cents off EPS. “The gains in our business came despite the impact of negative foreign currency exchange rates in Brazil, Canada and Chile, and a rather sluggish domestic retail environment where we still achieved an increase in average price per pair of 6.8 percent during the third quarter in our domestic wholesale business,” Chief Executive David Weinberg said in a statement. The company is “comfortable’ with current consensus estimates for the fourth quarter, he said. Shares are up 150% for the year through Thursday’s close, far outperforming the S&P 500, which is down 0.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

AbbVie’s stock tumbles after FDA warns on company’s Hep C treatments

AbbVie Inc.’s stock plunged 14% to an 18-month low in afternoon trade, after the Food and Drug Administration warned that the drug maker’s hepatitis C treatments, Viekira Pak and Technivie, can cause serious liver injury in patients with underlying advanced liver disease. Since Viekira Pak was approved by the FDA in December 2014, and Technivie was approved in July 2015, the FDA said there have been at least 26 cases worldwide of hepatic decompensation and liver failurein patients with underlying liver cirrhosis. “Patients taking these medicines should contact their health care professional immediately if they develop fatigue, weakness, loss of appetite, nausea and vomiting, yellow eyes or skin, or light-colored stools, as these may be signs of liver injury,” the FDA said in a statement. The FDA said patients shouldn’t stop taking these medicines with consulting a health care professional, as stopping treatment early could result in drug resistance to other hepatitis C medicines. AbbVie’s stock has dropped 30% year to date, while the S&P 500 has slipped 0.4%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

U.S. Attorney Bharara says charges against SAC Capital’s Steinberg to be dropped

WASHINGTON (MarketWatch) — U.S. Attorney Preet Bharara said his office will dismiss insider-trading charges against Michael Steinberg, a former trader at SAC Capital previously convicted. Six cooperating witnesses who also pleaded guilty will see charges dismissed. “The decision to dismiss these charges follows the Second Circuit’s Newman decision, and also reflects determinations, after careful consideration of all of our prior insider trading prosecutions, that insisting on maintaining guilty pleas in these cases would not be in the interests of justice,” the U.S. Attorney said. The move follows a Supreme Court decision that upheld the Newman ruling, which analysts have said will make insider-trading prosecutions more difficult.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

GNC sued by Oregon attorney general for using illegal ingredients

Oregon Attorney General Ellen Rosenblum said Thursday she has filed a lawsuit alleging that GNC Corp. sold dietary supplements that include illegal ingredients. The news sent shares of GNC down about 13% in afternoon trade. Rosenblum said various GNC products contain the synthetic chemical picamilon, or the stimulant BMPEA, both of which are not approved for sale in the U.S. The suit also alleges that some products included unlabeled BMPEA. “It is scary to know that certain products sold by GNC contain an ingredient that is not even labeled – let alone approved in the United States,” she said. The suit says Picamilon is a prescription drug used in some countries, but not the U.S., to treat neurological conditions. BMPEA is similar to an amphetamine that is banned by the World Anti-Doping Organization, it says. GNC shares are down this 26% year, while the S&P 500 is down 0.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Lumber Liquidators pleads guilty to Lacey Act violations

Lumber Liquidators Holdings Inc. has pleaded guilty to environmental crimes, related to the wood-flooring retailer’s illegal importation of hardwood flooring, according to a statement from the U.S. Department of Justice. Much of the flooring was illegally logged in Russia, in the habitat of endangered Siberian tigers and Amur leopards, and manufactured in China. The guilty plea is not related to a “60 Minutes” report earlier this year, that alleged the company sold wood flooring from China with high-levels of a cancer-causing agent. As part of the plea deal, Lumber Liquidators will pay $13.15 million, including $7.8 million in criminal fines, nearly $1 million in criminal forfeiture, $1.23 million in community service payments and $3.15 million through a related civil forfeiture. Lumber Liquidators was charged earlier this month with one felony count and four misdemeanor violations of the Lacey Act, which makes it illegal to import timber taken in violation of a foreign country’s laws. “Lumber Liquidators’ race to profit resulted in the plundering of forests and wildlife habitat that, if continued, could spell the end of the Siberian tiger,” said Assistant Attorney General John Cruden. “Lumber Liquidators knew it had a duty to follow the law, and instead it flouted the letter and spirit of the Lacey Act, ignoring its own red flags that its products likely came from illegally harvested timber, all at the expense of law abiding competitors.” The stock was up 0.4% in afternoon trade, but pared intraday gains of as much as 5% seen prior to the DOJ’s statement. The stock has tumbled 77% year to date, while the S&P 500 has lost 0.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Health-care stocks absent from stock-market rally

Health-care shares were being excluded from a stock-market run-up Thursday. The S&P 500’s health-care sector is the only one of the stock-market gauge’s 10 sectors in negative territory as equities mount one of their best advances since September. Health-care stocks slipped 0.9% in Thursday trading, while the average gain for the S&P’s other sectors, excluding health care, is up 1.8%. The downdraft in health-care marks a third consecutive session of declines in the sector and comes after a bruising Wednesday session for health-care and biotech shares a day after large pharmaceutical company Valeant Pharmaceuticals International Inc. plunged as much as 40% intraday on allegations from a short-seller. Shares of Valeant extended losses Thursday, falling a further 15%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Valeant extends losses as BMO downgrades stock

Valeant Pharmaceuticals International Inc. shares fell another 16% Thursday, extending their prior-session losses, after BMO downgraded the stock to market perform from outperform and said it cannot defend the company’s specialty pharma structure. The move comes a day after short seller Citron Research issued a damning report on Valeant, alleging revenue-recognition improprieties tied to specialty pharma companies. BMO estimates that about 10% of Valeant’s sales stem from such companies, which are also used by other big drug companies. But the structure of Valeant’s network seems different, said BMO analyst David Redfern. The company consolidates the financials of one pharma, Philidor, while other drug companies only work with “fully independent” companies. “Valeant’s structure may not be illegal, but we find it aggressive and questionable,” he said. “However, proof of a questionable business practice is not proof of financial wrong-doing.” BMO said an analysis of Valeant’s cash flows does not support the short seller’s claims, but it cannot be ruled out either. “So we’re left with their well-timed allegations, Valeant’s “categorical” denials and audited financial statements that support, but not necessarily prove Valeant’s position,” he wrote. “Thus, there is residual uncertainty that may not be fully resolved unless there is an investigation.” Valeant shares are down 43% this week, putting it on track for its worst-ever weekly performance, while the S&P 500 is up about 1%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Etsy shares rise after launch of manufacturing marketplace

Shares of Etsy rose 3.5% Thursday after the company announced the launch of the beta version of its manufacturing platform, and a day after the company posted its lowest ever closing price. Etsy previously announced it would be expanding the use of outside manufacturing, and this platform will be a marketplace for designers to connect with manufacturers. Shares of Etsy have fallen 40% in the past three months and 27% in the past month, compared to the S&P 500’s drop of 3% and gain of 5% respectively. Etsy’s stock had a closing price of $10.68 Wednesday.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

McDonald’s stock heads toward its biggest-ever price gain

McDonald’s Corp.’s stock ran up $7.18, or 7%, in morning trade Thursday, putting it on track to post the biggest-ever one-day price gain in its history, by far. The stock was also on track for a record close, after the fast-food giant reported better-than-expected third-quarter earnings, revenue and same-store sales. The second-biggest price gain was the $4.86 surge it produced on Oct. 28, 2008, amid a near 900-point run up in the Dow Jones Industrial Average off a 5 1/2-year low, followed by the $4.49 rally on Jan. 29, 2015 after the company said its CEO was retiring. On a percentage basis, the stock’s rally would be the 36th-biggest, way behind the 47% jump on Sept. 25, 1984.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News